AACR 2021 Targeting B7 H3 in SCCHN Preclinical PoC MGC018 investigational anti B7 H3 ADC

MacroGenics Inc. published this content on March 24, 2021, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 23, 2025 at 16:39 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]